A Phase I Dose-Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BI-505, a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Advanced Multiple Myeloma.

Trial Profile

A Phase I Dose-Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BI-505, a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Advanced Multiple Myeloma.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Feb 2015

At a glance

  • Drugs BI 505 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 04 Apr 2013 Preliminary results have been presented at the International Myeloma Workshop according to a BioInvent International media release.
    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Jan 2013 Preliminary results have been reported in a BioInvent International media release. Data showed that the drug is associated with an acceptable tolerability profile and has established BI 505 dosed at 10 mg/kg for further investigation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top